Abnormal platelet response to PAF and ADP in beta-thalassaemia.
1. AGEPC (2 microM) caused a noticeable increment in platelet aggregation, in increasing order, in 9 heterozygous beta-thalassaemic subjects, 18 homozygous beta-thalassaemics and 12 splenectomized homozygous beta-thalassaemics. 2. Recombination experiments with "patient" platelets and "normal" plasma or the reverse, as well as hydrolysis of labelled AGEPC from "normal" and "patient" serum, suggested that the observed abnormalities were due to platelets rather than to the plasma PAF hydrolase. 3. A normal splenectomized subject showed also hyperaggregability and PAF serum levels in a splenectomized patient were found twice as high in a non-splenectomized patient. 4. ADP (5 microM) caused decreased or normal platelet aggregation in the homozygous patients, approximately normal in the heterozygous subjects and increased in the splenectomized patients.
Demopoulos
C A
CA
University of Athens, Department of Food Chemistry, Greece.
Andrikopoulos
N K
NK
Stathopoulou-Sparou
R
R
D000244:Adenosine Diphosphate / Q000494:pharmacology*; D006580:Genetic Carrier Screening; D006720:Homozygote; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D010972:Platelet Activating Factor / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D012016:Reference Values; D013156:Splenectomy; D013789:Thalassemia / Q000097:blood* / Q000235:genetics
D010972:Platelet Activating Factor; D000244:Adenosine Diphosphate